Patents by Inventor Joem Schmidt

Joem Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170007582
    Abstract: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 12, 2017
    Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert P. Pauly, Christopher H.S. McIntosh, Ray A. Pederson
  • Publication number: 20130116290
    Abstract: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 9, 2013
    Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert P. Pauly, Christopher H.S. McIntosh, Ray A. Pederson
  • Publication number: 20050107309
    Abstract: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.
    Type: Application
    Filed: December 22, 2004
    Publication date: May 19, 2005
    Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert Pauly, Christopher McIntosh, Ray Pederson
  • Publication number: 20020110560
    Abstract: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.
    Type: Application
    Filed: April 5, 2002
    Publication date: August 15, 2002
    Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert P. Pauly, Christopher H.S. McIntosh, Ray A. Pederson
  • Patent number: 6303661
    Abstract: Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: October 16, 2001
    Assignee: Probiodrug
    Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert P. Pauly, Christopher H. S. McIntosh, Ray A. Pederson